Literature DB >> 2963690

Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer.

F Pekonen1, S Partanen, T Mäkinen, E M Rutanen.   

Abstract

Levels of epidermal growth factor receptor (EGF-R) and insulin-like growth factor receptor (IGF-R) in breast cancer tissue were evaluated. The binding of growth factors was compared to the content of estrogen receptors (ER) and progesterone receptors (PgR). EGF-R correlated negatively to the ER and PgR (Kendall correlation, P less than 0.001), whereas the IGF-R correlated positively to ER and PgR (analysis of variance, P less than 0.001). In contrast, no correlation was found between EGF-R and IGF-R. IGF-R binding was higher in tumor tissues than in adjacent normal tissues (Wilcoxon rank test, P less than 0.001), whereas the EGF-R binding in normal tissue did not differ from that in cancer tissue. The degree of differentiation in ductal breast cancer correlated to EGF-R (chi 2 test, P = 0.018), but not to IGF-R. The bindings of both growth factors were the same in metastases and primary breast tumors. Our results show that EGF-R and IGF-R are present in normal breast tissue and breast cancer tissue. The growth factor receptors are related to steroid receptor content and their presence is associated with malignant transformation of breast cells and dedifferentiation of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2963690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Biochemical study of cyst fluid in human breast cystic disease: a review.

Authors:  C L Enriori; J E Novelli; M del C Cremona; R J Hirsig; P J Enriori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer.

Authors:  J L Formento; M Francoual; P Formento; M C Etienne; J L Fischel; M Namer; M Frenay; E François; G Milano
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

Review 3.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 4.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

5.  Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases.

Authors:  J D Jacquemier; J Hassoun; M Torrente; P M Martin
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

6.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.

Authors:  C L Arteaga; L J Kitten; E B Coronado; S Jacobs; F C Kull; D C Allred; C K Osborne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

7.  Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.

Authors:  R E Favoni; A de Cupis; A Perrotta; S Sforzini; D Amoroso; F Pensa; L Miglietta
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.

Authors:  K Szepeshazi; S Milovanovic; K Lapis; K Groot; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 9.  CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Authors:  Cynthia A Zahnow
Journal:  Expert Rev Mol Med       Date:  2009-04-08       Impact factor: 5.600

10.  IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients.

Authors:  Michal Rajski; Rosanna Zanetti-Dällenbach; Brigitte Vogel; Richard Herrmann; Christoph Rochlitz; Martin Buess
Journal:  BMC Med       Date:  2010-01-05       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.